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To the Editor: The question of whether cardiac func-tensive medications were modified during the study pe-
tion improves or worsens after initiation of dialysis ther-riod. If angiotensin-converting enzyme inhibitors were
apy is still open. The paper by Foley et al [1] is a stepstarted after the first year, this would explain, at least in
forward towards resolving this issue. The authors con-some patients, why further significant LVM enlargement
cluded that left ventricular dilation with compensatorydid not develop [4].
hypertrophy continued after the start of dialysis therapy,Finally, I do not share the authors’ conclusion that
particularly in the first year of therapy. A few relevantintervention beyond the first year of dialysis treatment
papers concerning this problem were published earlier,might be relatively ineffective to prevent progressive
but the Authors did not cite them [2, 3].cardiac enlargement. In contrast, I think that the rela-
The study by Foley et al was prospective. The patienttively normal blood pressure levels and desirable hemo-
subset was highly selected: only 29 of 433 patients whoglobin levels achieved prevented progression beyond one
started the study were analyzed. The patient subset wasyear. Indeed, previous studies demonstrated a significant
older than the parent population—58 vs. 51 years. Ageregression in LVM index after partial correction of ane-
is one of the major risk factors for the development ofmia with erythropoietin [5]. The problem remaining to
congestive heart failure in dialysis patients. The preva-be solved is why a significant cardiac enlargement devel-
lence of congestive heart failure was 21% at the startoped during the first year of the study, in spite of blood
of the study. The number of patients who developedpressure and hemoglobin levels comparable with those
congestive heart failure during the 41-month follow-upof the later periods.
is not given. Because cardiovascular response differsIn conclusion, much effort should be made to prevent
among hemodialysis (HD) patients and peritoneal dial-currently known risk factors from developing during the
ysis patients [4], we believe that echocardiographic find-entire course of the dialysis therapy, though further stud-
ings in these two groups should be analyzed separately.ies are needed to find out the exact mechanisms responsi-
It is very likely that hyperparathyroidism contributesble for the progressive cardiac enlargement.
to left ventricular hypertrophy (LVH) in dialysis patients
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look at the risk factors for the progression of cardiomeg-
aly in dialysis patients, the parameters describing para-
thyroid function must be taken into account. Because
parathyroid function fluctuates as dialysis is continued
and PTH concentration varies irrespective of the dura- 1999 by the International Society of Nephrology
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